AbbVie proclaims a $380 million funding in API amenities in North Chicago
AbbVie has introduced plans to speculate $380 million to construct two new energetic pharmaceutical ingredient (API) manufacturing amenities at its present location in North Chicago, Illinois, US.
These amenities will combine superior manufacturing applied sciences and AI to help the manufacturing of the corporate’s weight problems and neuroscience medicines.
Uncover B2B advertising and marketing that delivers
Mix enterprise intelligence and editorial excellence to succeed in engaged professionals throughout 36 main media platforms.
Extra info
Development is scheduled to start out in spring 2026 and each amenities are anticipated to be absolutely operational in 2029.
AbbVie plans to recruit 300 workers in North Chicago, together with manufacturing operators, scientists, laboratory technicians and engineers, to help its expanded operations.
Manufacturing APIs is a posh, multi-step course of that creates the parts important to a drug’s therapeutic results.
Over the previous six months, AbbVie has unveiled plans to considerably enhance its API manufacturing capability within the US.
In September 2025, the corporate broke floor on the primary part of this funding, a chemical synthesis facility aimed toward shifting API manufacturing for sure neuroscience, immunology and oncology merchandise from Europe and Asia again to the US.
AbbVie employs roughly 29,000 individuals within the US, together with greater than 6,000 at its US manufacturing websites.
Along with the newest funding, AbbVie not too long ago unveiled plans to amass a tool manufacturing facility in Arizona and make substantial investments within the Massachusetts location. Additional investments in different US states are anticipated to be introduced in 2026.
Robert Michael, Chairman and CEO of AbbVie, stated: “This milestone demonstrates additional progress towards our dedication of $100 billion in U.S. R&D and capital investments over the subsequent decade.
“By strengthening our U.S. manufacturing capabilities, we’re nicely positioned to help our investments in innovation and enhance our means to ship next-generation medicines to sufferers.”
In August 2025, AbbVie signed a definitive settlement to amass Gilgamesh Prescription drugs’ lead investigational candidate bretisilocin for as much as $1.2 billion, together with an upfront cost and improvement milestones.
